Work

S1200 Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study

Year: 2024

Type: conference-abstract

Source: The American Journal of Gastroenterology

DOI: 10.14309/01.ajg.0001034168.98973.2c

Authors: Raymond K. Cross, Silvio Danese, Douglas C. Wolf, Katsuyoshi Matsuoka, Iris Dotan, Brigid S. Boland, Laura E. Raffals, Dimpy Mehra, Norma Ruiz Santiago, AnnKatrin Petersen, Manik Desai, Hsiuanlin Wu, Dong Wang, Mark T. Osterman, Anjali Jain, James O. Lindsay

Institutions: Mercy Medical Center, Mercy Medical Center, Humanitas University, Atlanta Gastroenterology Associates, Toho University, Toho University Medical Center Sakura Hospital, Tel Aviv University, Rabin Medical Center, University of California San Diego, Mayo Clinic, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Japan), Queen Mary University of London

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403725419

Cites:

Cited by:

Related to: 10